Better results, starting now: your nutrition roadmap for GLP-1 therapy
Obesity is a defining health challenge of our time. Affecting more than 1 billion people globally, it contributes to millions of preventable deaths each year. Yet, for too long, the global response has been fragmented, underfunded, and hindered by the outdated view of obesity as a mere ‘lifestyle choice’. In reality, it is a multifactorial chronic, progressive, and relapsing disease.
A pivotal shift occurred on December 1, 2025, when the World Health Organization (WHO) released its first-ever clinical guidelines recommending GLP-1 receptor agonists for the long-term treatment of obesity. At the same time, the WHO emphasized that these drugs are not a standalone solution: they work best when combined with comprehensive nutrition and lifestyle support, rather than replacing it.1

Fuelling your journey: a plant-forward approach
This guide bridges the gap between clinical treatment and everyday plate-based solutions. Developed by a multidisciplinary team of dietitians, public health nutritionists, and food technology experts, it offers an evidence-based roadmap for supporting GLP-1 therapy.
By prioritizing a sustainable, plant-forward approach, we provide the practical tools needed to use food as medicine – optimizing your health outcomes today while protecting the planet for tomorrow.

What GLP-1 does naturally
Glucagon-like peptide-1 (GLP-1) is a hormone produced naturally in your small intestine and brain. It is released immediately after you eat to signal to your body that fuel has arrived.2
The three main tasks of natural GLP-1:
- In the brain: it acts as a ‘fullness switch’, telling your brain that you have had enough to eat, which naturally reduces your appetite and interest in food.
- In the stomach: it slows down digestion (gastric emptying). This keeps food in your stomach longer, helping you feel satisfied for an extended period after a meal.
- In the pancreas: it signals the pancreas to release insulin and suppress glucagon secretion, which helps manage blood sugar levels by moving glucose into your cells and reducing its release to the bloodstream.
How GLP-1 drugs work
While our natural GLP-1 hormone is very effective, it is also very short-lived – the body breaks it down in just a few minutes. GLP-1 medications are designed to mimic this natural hormone but are modified to last much longer in the system. This provides a steady, sustained signal of fullness that helps manage the chronic nature of obesity more effectively than the body’s natural ‘bursts’ of the hormone. This results in improved glycemic control, substantially reduced caloric intake and consequent weight reduction.3 4 5 6
As of 2026, several medications are approved by health authorities specifically for chronic weight management. While you may recognize these active ingredients from diabetes treatments, they are prescribed under specific names when used for weight health.7
Primary medications for weight loss
- Tirzepatide (Zepbound): a weekly injection that mimics two hormones (GLP-1 and Glucose-dependent insulinotropic polypeptide – GIP) to reduce appetite and improve how the body breaks down sugar and fat.8
- Semaglutide (Wegovy): available as a weekly injection or a daily oral tablet. It mimics the GLP-1 hormone to help you feel full sooner and for longer.9
- Liraglutide (Saxenda): a daily injection often used by those who prefer a shorter-acting medication or are just beginning therapy.10
A note on brand names
You may also hear names like Ozempic11 or Mounjaro.12 While these contain the same active ingredients (Semaglutide and Tirzepatide), they are officially approved and labeled for Type 2 Diabetes.13 Your healthcare provider will determine which version and dosage is right for your specific health needs.
Why complementary nutritional and lifestyle changes are important
While GLP-1 receptor agonists represent a breakthrough in treating obesity as a chronic disease, they are most effective when paired with high-quality nutrition and lifestyle changes. The WHO emphasizes that these medications should be integrated with – rather than replace – intensive interventions to address the complex nature of obesity. Because these therapies often reduce appetite, focusing on nutrient-dense foods is essential to ensure the body receives vital vitamins and minerals from smaller portions. A strategic nutritional approach also helps preserve lean muscle mass, which is critical for maintaining a healthy metabolism during weight loss. By adopting a ‘food as medicine’ mindset, patients can better manage potential side effects and improve long-term metabolic outcomes. Ultimately, this synergy between clinical treatment and lifestyle habits creates a sustainable foundation for lasting health. This multi-modal strategy ensures that weight loss is not just a temporary change, but a permanent transition to lifelong vitality.14 15 16
Why a plant-forward approach complements GLP-1 therapy and weight loss goals
As GLP-1 medications shift your physiological relationship with food, a plant-forward nutritional strategy provides the ideal framework for success. This approach aligns with how the body responds to treatment while maximizing long-term health benefits.17 18
1. Working with your changing appetite
GLP-1 receptor agonists reduce hunger by slowing gastric emptying, increasing satiety signals, and dampening the brain’s reward signals for ‘heavy’ foods. Current data shows a shift in preferences: patients often report a decrease in the consumption of beef, pork, dairy and fried foods. Conversely, fruits, leafy greens, and water are often the categories to see an increase in intake.19 A plant-forward diet naturally leans into these shifting cravings, focusing on the fresh, light, and hydrating foods the body begins to prioritize.20
2. The power of fiber
A primary advantage of a plant-forward approach is its high fiber content. Systematic reviews consistently show that higher dietary fiber intake is favorably associated with successful weight management and a reduced risk of type 2 diabetes, cardiovascular disease, and cancer.21 22 23 Fiber works in tandem with GLP-1 therapy to promote satiety, stabilize blood sugar, and support gut health, providing a dual-action mechanism for weight health.24
3. Prioritizing nutrient density
Because GLP-1 therapy leads to eating smaller portions, every calorie consumed must provide high nutritional value. Plant-forward diets emphasize nutrient-dense foods such as vegetables, fruits, whole grains, legumes, nuts, and seeds. These foods are rich in fiber, vitamins, minerals and phytonutrients with antioxidant properties.25 By following a plant-forward dietary pattern during GLP-1 therapy, patients can achieve a caloric deficit while helping their bodies remain nourished and reducing the long-term health risks associated with obesity.26 27
The GLP-1 balanced plant-based plate
When your appetite is smaller, every bite must work harder. This plate is specifically designed to maximize nutrient density, protect your muscle mass, and support digestive comfort while on GLP-1 therapy. This approach is inspired by the expert consensus statement by Sievenpiper and colleagues (2026) on nutritional management for individuals treated with GLP-1 receptor agonists.28
1. The Rainbow Base
Fruits & Vegetables (~50% of Plate)
- 5-a-Day: Aim for 3 veg and 2 fruit portions daily.
- Go Green: Prioritize leafy greens for essential minerals.
- Iron Hack: Pair Vitamin C with lentils or oats to boost absorption.
- Easy Access: Frozen and pre-washed options are just as healthy.
2. Muscle Power
Protein (25–30% of Plate)
- Protein First: Eat this first to hit targets before you feel full.
- The Goal: Aim for 80–120g daily; spread 20–30g across each meal.
- Top Picks: Legumes, tofu, tempeh, and fortified soy dairy.
- Bonus Sources: Grains like quinoa and oats also add to your protein total.
3. Smart Energy
Smart Energy Carbohydrates (20-25% of Plate)
- Quality Fuel: Focus on whole-grain like oats and brown rice for fiber.
- No Extremes: Carbs are vital for energy—avoid severe restriction.
- Swap Up: Choose whole-grain bread and pasta over white versions.
- Stay Comfort: Use white rice or peeled potatoes if digestion feels “heavy.”
4. Smart Hydration
Timing and Quality
- 30/60 Rule: Wait 30–60 mins after eating to drink; avoid “filling up” during meals.
- Daily Goal: Aim for 2–3L of fluids (more if exercising or in heat).
- Top Picks: Water and unsweetened teas are the gold standard.
- Over 60s: Drink intentionally, as thirst signals can naturally decrease.
5. Brain & Heart Fats
Healthy Fats (Small Portions)
- Choose Wisely: Focus on Omega-3s (flax, chia, walnuts) and olive oil.
- Vitamins: Healthy fats are essential for absorbing vitamins A, D, E, and K.
- Watch the Gap: Limit fats to 30% of your energy to manage calorie density.
- Avoid: Skip palm/coconut oil and fried foods.
6. The Fortified Boost
Nutrient Density in Small Bites
- Calcium Boost: Aim for 2 daily servings of fortified soy milk or yogurt.
- Label Check: Choose cereals and plant-based meat alternatives with added Iron and B12.
- Flavor Hack: Use nutritional yeast for a cheesy taste plus B-vitamins.
- Iodine: Use iodised salt in moderation to support thyroid health.
7. Targeted Support
Strategic Supplementation
- Essentials: Vitamin B12 and Algae-based Omega-3s (EPA/DHA) are key.
- As Needed: Vitamin D for immunity and Iron for blood health.
- Gut Regularity: Use Psyllium husk to manage intestinal symptoms if needed.
- Muscle Care: Use protein powder if you can’t hit targets with meals.
8. Nutrient Back-up
Meal Replacements
- When to Use: Ideal for early fullness or low-calorie days.
- Schedule: Replace 1–2 meals daily for weight loss, or 3–6 weekly for weight maintenance.
- The Formula: Look for 250–400 kcal and 20–30g of protein.
- Fiber Check: Ensure at least 7g of fiber per serving.
Download the full GLP-1 nutrition guide
Explore how to bridge the gap between clinical treatment and everyday plate-based solutions. Developed by a multidisciplinary team of dietitians and health experts, this guide provides our evidence-based ’recipe’ for your success.
Authors
Lucas Oliveira, Nutritionist, ProVeg International
Anna-Lena Klapp, Head of Research, ProVeg International
We would like to thank the following people for sharing their time, expertise, and thoughtful review of the brochure:
Valentina Gallani, Health & Nutrition Manager, ProVeg International
Veronika Mlynárik Baťová, Senior Nutrition Specialist, ProVeg Czech Republic
Laura Weinhold, Dietitian & Food Services Specialist, ProVeg Germany
Stefany Guerreiro Lima, Food and Nutrition Project Manager, ProVeg Brasil
References
- WHO issues global guideline on the use of GLP-1 medicines in treating obesity. December 2025. Available at: https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi:10.1016/j.molmet.2019.09.010
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi:10.1016/j.molmet.2019.09.010
- Forst T, De Block C, Del Prato S, et al. Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes. Diabetes Obes Metab. 2025;27 Suppl 2:48-65. doi:10.1111/dom.16247
- Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024;332(7):571-584. doi:10.1001/jama.2024.10816
- Fredrick TW, Camilleri M, Acosta A. Pharmacotherapy for Obesity: Recent Updates. Clin Pharmacol. 2025;17:305-327. Published 2025 Sep 19. doi:10.2147/CPAA.S497904
- Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. Published online January 14, 2026. doi:10.1016/S0140-6736(25)02105-1
- Eli Lilly and Company, Zepbound. Tirzepatide injection, solution, Prescribing Information, 2024. Available from: https://uspl.lilly.com/zepbound/zepbound.html#pi.
- Novo Nordisk, Wegovy. Semaglutide injection 2.4 mg, Prescribing Information, 2024. Available at: https://www.novo-pi.com/wegovy.pdf.
- Novo Nordisk, Saxenda. Liraglutide injection 3 mg, Prescribing Information, 2024. Available at: https://www.novo-pi.com/saxenda.pdf.
- Administration USFD.OZEMPIC® (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf. Accessed February 03, 2026.
- Administration USFD. MOUNJAROTM (tirzepatide) Injection, for subcutaneous use initial U.S. Approval: 2022. 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf. Accessed February 03, 2026.
- Long B, Pelletier J, Koyfman A, Bridwell RE. GLP-1 agonists: A review for emergency clinicians. Am J Emerg Med. 2024;78:89-94. doi:10.1016/j.ajem.2024.01.010
- WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Obes Pillars. 2025;15:100181. Published 2025 Jun 3. doi:10.1016/j.obpill.2025.100181
- Fitch A, Gigliotti L, Bays HE. Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions. Obes Pillars. 2025;16:100205. Published 2025 Aug 28. doi:10.1016/j.obpill.2025.100205
- Ben-Porat T, Sherf-Dagan S, Côté M, Miner CJ, Buch A. Nutritional Challenges of Incretin-Based Obesity Management Medications: Implications for Clinical Practice. Adv Nutr. 2025;16(11):100522. doi:10.1016/j.advnut.2025.100522
- Sievenpiper JL, Ard J, Blüher M, et al. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 – based therapies: An expert consensus statement using a modified Delphi approach. Obes Pillars. 2025;17:100228. Published 2025 Nov 11. doi:10.1016/j.obpill.2025.100228
- Dilley A, Adhikari S, Silwal P, Lusk JL, McFadden BR. Characteristics and food consumption for current, previous, and potential consumers of GLP-1 s. Food Qual Prefer 2025;129:105507.
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Obes Pillars. 2025;15:100181. Published 2025 Jun 3. doi:10.1016/j.obpill.2025.100181
- Veronese N, Solmi M, Caruso MG, et al. Dietary fiber and health outcomes: an umbrella review of systematic reviews and meta-analyses. Am J Clin Nutr. 2018;107(3):436-444. doi:10.1093/ajcn/nqx082
- Reynolds AN, Cummings J, Tannock G, Mann J. Dietary fibre as an essential nutrient. Nat Food. 2026;7(1):4-5. doi:10.1038/s43016-025-01282-0
- Jovanovski E, Mazhar N, Komishon A, et al. Effect of viscous fiber supplementation on obesity indicators in individuals consuming calorie-restricted diets: a systematic review and meta-analysis of randomized controlled trials. Eur J Nutr. 2021;60(1):101-112. doi:10.1007/s00394-020-02224-1
- Ben-Porat T, Sherf-Dagan S, Côté M, Miner CJ, Buch A. Nutritional Challenges of Incretin-Based Obesity Management Medications: Implications for Clinical Practice. Adv Nutr. 2025;16(11):100522. doi:10.1016/j.advnut.2025.100522
- Rockström J, Thilsted SH, Willett WC, et al. The EAT–Lancet Commission on healthy, sustainable, and just food systems. Lancet. 2025;406(10512):1625-1700. doi:10.1016/S0140-6736(25)01201-2.
- Ben-Porat T, Sherf-Dagan S, Côté M, Miner CJ, Buch A. Nutritional Challenges of Incretin-Based Obesity Management Medications: Implications for Clinical Practice. Adv Nutr. 2025;16(11):100522. doi:10.1016/j.advnut.2025.100522
- Almandoz JP, Wadden TA, Tewksbury C, et al. Nutritional considerations with antiobesity medications. Obesity (Silver Spring). 2024;32(9):1613-1631. doi:10.1002/oby.24067
- Sievenpiper JL, Ard J, Blüher M, et al. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 – based therapies: An expert consensus statement using a modified Delphi approach. Obes Pillars. 2025;17:100228. Published 2025 Nov 11. doi:10.1016/j.obpill.2025.100228
